A practical method of I-131 thyroid cancer therapy dose optimization using estimated effective renal clearance.

Abstract

In thyroid cancer patients with renal impairment or other complicating factors, it is important to maximize I-131 therapy efficacy while minimizing bone marrow and lung damage. We developed a web-based calculator based on a modified Benua and Leeper method to calculate the maximum I-131 dose to reduce the risk of these toxicities, based on the effective renal clearance of I-123 as measured from two whole-body I-123 scans, performed at 0 and 24 h post-administration.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1177/2050313X17745203

Publication Info

Howard, Brandon A, Olga G James, Jennifer M Perkins, Robert A Pagnanelli, Salvador Borges-Neto and Robert E Reiman (2017). A practical method of I-131 thyroid cancer therapy dose optimization using estimated effective renal clearance. SAGE Open Med Case Rep, 5. 10.1177/2050313X17745203 Retrieved from https://hdl.handle.net/10161/16135.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Howard

Brandon Augustus Howard

Assistant Professor of Radiology
Borges-Neto

Salvador Borges-Neto

Professor of Radiology

Expertise:

1. Diagnostic and Prognostic Utility of Cardiovascular Nuclear Medicine in  Heart Disease.
2. The Role of Cardiac PET/CT  in Cardiac Sarcoidosis and Ischemic Heart Disease.
3. The Role of Nuclear Cardiology in Diagnosis and Management of Amyloidosis.
4. Left Ventricular Dyssynchrony Evaluation by GSPECT.

I am a Professor of Radiology (Nuclear Medicine) and Internal Medicine at Duke University Medical Center. I also serve as the Medical Director of Nuclear Cardiology at Duke Health System with Duke Heart Center. I received my medical doctorate from the Federal Fluminense University in Brazil. I subsequently completed a Cardiology Fellowship at Antonio Pedro University Hospital in Brazil and a second Fellowship in the Medicine/Cardiovascular division at Brigham and Women's Hospital in Boston. I continued my education with a fellowship in Nuclear Cardiology at the Methodist Hospital Baylor College of Medicine in Houston, Texas and finally in Nuclear Medicine in the Department of Radiology at Duke University Medical Center. I have lectured extensively internationally and have published 130+ publications in peer reviewed scientific professional journals. I am a founding member of the American Society of Nuclear Cardiology, Fellow of the American College of Cardiology, Fellow of the American College of Nuclear Medicine and Fellow of the American Heart Association. My clinical and Research interests include the role of cardiac imaging in predicting outcomes and guiding therapy. I have developed one of the largest Nuclear Cardiology Data Bases in the US. More recently my primarily research interest also includes the use of New Radiopharmaceuticals for the Diagnosis and Treatment of Oncologic Diseases (Theranostics). I have led a Team for the implementation of Diagnosis and Treatment of Neuroendocrine Tumors which became a Center of Reference for this Disease Diagnosis and Treatment with PRRT. serving as the PI for Expanded Access for Therapeutic Use of 177-Lu-DOTAO-Tyr3-Octreotide (Advanced Accelerator Applications SA – AAA) –Compationate Use – “177 Lu-Dotatate for Midgut Neuroendocrine Tumors and 177 Lu-Dotatate for GPENET’. Clinical Trials.Gov. 

Reiman

Robert Ellis Reiman

Associate Professor of Radiology

Dr. Reiman is diplomate of the American Board of Nuclear Medicine, and is the Associate Director the Radiation Safety Division of Duke's Occupational and Environmental Safety Office.  He is on the faculty the Department of Radiology and is a member of the Faculty of the Duke Medical Physics Graduate Program.  He coordinates the patient care activities of the Duke Radiation Safety Division and participates in the teaching of radiology residents, nuclear medicine fellows, cardiology fellows and medical students.  His current research interests include internal radionuclide dosimetry and the application of Web-based systems to problems in radiation safety and dosimetry.  He has also published on imaging of bone, brain and soft-tissue tumors with nitrogen-13 labeled amino acids.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.